Biopharma & Life Sciences
Cogent Biosciences Executive Compensation (FY25)
COGT · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): June 11, 2026
260 figures on this page: 257 cited to the filing that reported them, 3 calculated from figures it prints. See the citations
Andrew Robbins, Chief Executive Officer, President and Director, received $27,762,684 in total compensation for fiscal 2025, and compared with the $4,917,890 reported for fiscal 2024, Robbins' total was up. The disclosed chief executive pay ratio for fiscal 2025 is 95:1, against median employee compensation of $292,285. Shareholders recorded 90.2% support for the say-on-pay proposal at the meeting held April 13, 2026 for fiscal 2025. Companies named in the disclosed peer group include Allogene Therapeutics, Inc., AnaptysBio, Inc., Arcus Biosciences, Inc., Arvinas, Inc. and Bicycle Therapeutics plc, among others.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Andrew Robbins: $4,917,890 → $27,762,684
Frequently asked questions
Answers drawn from the data on this page.
Who is Cogent Biosciences' chief executive and what were they paid?
Andrew Robbins, Chief Executive Officer, President and Director, received $27,762,684 in total compensation for fiscal 2025. Compared with the $4,917,890 reported for fiscal 2024, Robbins' total was up.
What was Cogent Biosciences' say-on-pay result?
Shareholders recorded 90.2% support for the say-on-pay proposal at the meeting held April 13, 2026 for fiscal 2025.
Which companies are in Cogent Biosciences' peer group?
Companies named in the disclosed peer group include Allogene Therapeutics, Inc., AnaptysBio, Inc., Arcus Biosciences, Inc., Arvinas, Inc. and Bicycle Therapeutics plc, among others. The peer group established December 2025 includes Amicus Therapeutics, Inc., Apellis Pharmaceuticals, Inc., BridgeBio Pharma, Inc., CG Oncology, Inc. and Corcept Therapeutics Incorporated, among others.
What is Cogent Biosciences' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 95:1, against median employee compensation of $292,285.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Andrew Robbins Chief Executive Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | — | ◇ |
Jessica Sachs Chief Medical Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
John Robinson Chief Scientific Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Andrew Robbins Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Cole Pinnow Chief Commercial Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | — | ◇ |
Jessica Sachs Chief Medical Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
John Robinson Chief Scientific Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
John Green Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Andrew Robbins Chief Executive Officer, President and Director | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Jessica Sachs Chief Medical Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
John Robinson Chief Scientific Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Cole Pinnow Chief Commercial Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
John Green Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Andrew Robbins | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Andrew Robbins | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Andrew Robbins | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Andrew Robbins | PSU | ◇ | — | ◇ | — | ◇ | — | ◇ |
| Cole Pinnow | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Cole Pinnow | PSU | ◇ | — | ◇ | — | ◇ | — | ◇ |
| Cole Pinnow | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Cole Pinnow | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Jessica Sachs | PSU | ◇ | — | ◇ | — | ◇ | — | ◇ |
| Jessica Sachs | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Jessica Sachs | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Jessica Sachs | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| John Green | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| John Green | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| John Green | PSU | ◇ | — | ◇ | — | ◇ | — | ◇ |
| John Green | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| John Robinson | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| John Robinson | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| John Robinson | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| John Robinson | PSU | ◇ | — | ◇ | — | ◇ | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Andrew Robbins | Option | ◇ | — | ◇ | 2/12/2033 |
| Option | ◇ | — | ◇ | 1/22/2035 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/22/2034 | |
| Option | ◇ | — | ◇ | 12/16/2035 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/24/2032 | |
| John Green | Option | ◇ | — | ◇ | 12/16/2035 |
| Option | ◇ | — | ◇ | 1/22/2034 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/12/2033 | |
| Option | ◇ | — | ◇ | 1/22/2035 | |
| Option | ◇ | — | ◇ | 1/24/2032 | |
| RSU | ◇ | ◇ | — | — | |
| Jessica Sachs | Option | ◇ | — | ◇ | 1/24/2032 |
| Option | ◇ | — | ◇ | 1/22/2034 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 12/16/2035 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/22/2035 | |
| Option | ◇ | — | ◇ | 2/12/2033 | |
| Cole Pinnow | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 01/22/2035 | |
| Option | ◇ | — | ◇ | 05/24/2034 | |
| Option | ◇ | — | ◇ | 12/16/2035 | |
| John Robinson | Option | ◇ | — | ◇ | 1/24/2032 |
| Option | ◇ | — | ◇ | 1/22/2035 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 12/16/2035 | |
| Option | ◇ | — | ◇ | 2/12/2033 | |
| Option | ◇ | — | ◇ | 1/22/2034 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Peter Harwin Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Todd Shegog | ◇ | — | ◇ | — | — | — | ◇ |
Arlene M. Morris | ◇ | — | ◇ | — | — | — | ◇ |
Chris Cain | ◇ | — | ◇ | — | — | — | ◇ |
Karen Ferrante | ◇ | — | ◇ | — | — | — | ◇ |
Matthew E. Ros | ◇ | — | ◇ | — | — | — | ◇ |
Andrew Robbins served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Compensation committee chair | ◇ |
| Nominating and governance chair | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Allogene Therapeutics, Inc. ALLO
- AnaptysBio, Inc. ANAB
- Arcus Biosciences, Inc. RCUS
- Arvinas, Inc. ARVN
- Bicycle Therapeutics plc BCYC
- Blueprint Medicines Corporation BPMC
- Celldex Therapeutics, Inc. CLDX
- Day One Biopharmaceuticals, Inc. DAWN
- Erasca, Inc. ERAS
- IGM Biosciences, Inc. IGMS
- Immunome, Inc. IMNM
- Iovance Biotherapeutics, Inc. IOVA
- Kiniksa Pharmaceuticals, Ltd. KNSA
- Kura Oncology, Inc. KURA
- Nuvalent, Inc. NUVL
- Relay Therapeutics, Inc. RLAY
- SpringWorks Therapeutics, Inc. SWTX
- Syndax Pharmaceuticals, Inc. SNDX
- Tyra Biosciences, Inc. TYRA
- Xencor, Inc. XNCR
peer group established December 2025
- Amicus Therapeutics, Inc. FOLD
- Apellis Pharmaceuticals, Inc. APLS
- BridgeBio Pharma, Inc. BBIO
- CG Oncology, Inc. CGON
- Corcept Therapeutics Incorporated CORT
- Crinetics Pharmaceuticals, Inc. CRNX
- Cytokinetics, Incorporated CYTK
- IDEAYA Biosciences, Inc. IDYA
- Immunovant, Inc. IMVT
- Mirum Pharmaceuticals, Inc. MIRM
- Revolution Medicines, Inc. RVMD
- TG Therapeutics, Inc. TGTX
- Ultragenyx Pharmaceutical Inc. RARE
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | April 13, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 4, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 5, 2024 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Cogent Biosciences disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Cogent Biosciences sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
260 figures on this page: 257 cited to the filing that reported them, 3 calculated from figures it prints.
257 cited to the filing
3 calculated from the filing
Documents cited
- 0001193125-26-267566Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001193125-26-1738342025 Summary Compensation Table · CEO PAY RATIO · Fiscal Year 2025 Director Compensation Table · Grants of Plan-Based Awards · and 2 more sections
- 0001193125-25-135337Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001193125-25-089237Summary Compensation Table
- 0001193125-24-155116Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-24-107124Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Cogent Biosciences executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/COGT (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Cogent Biosciences and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Cogent Biosciences discloses
The companies named in COGT's own disclosed peer group.
Allogene Therapeutics, Inc.Arcus Biosciences, Inc.Arvinas, Inc.Kura Oncology, Inc.Relay Therapeutics, Inc.Syndax Pharmaceuticals, Inc.Xencor, Inc.Amicus Therapeutics, Inc.Apellis Pharmaceuticals, Inc.BridgeBio Pharma, Inc.Crinetics Pharmaceuticals, Inc.Cytokinetics, IncorporatedIDEAYA Biosciences, Inc.Mirum Pharmaceuticals, Inc.Ultragenyx Pharmaceutical Inc.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}